JNJ Surges 59.3%, But Analysts See Potential Downside

Johnson & Johnson (JNJ) stock has been on a tear, surging by 59.3% in the past year to hit $275.66 as of September 4th.

The company's performance can be attributed to several key events, including the FDA approval of its Ottava robotic surgery platform and the approval of IMAAVY (nipocalimab) for warm autoimmune hemolytic anemia, expanding its commercial reach.

Additionally, Johnson & Johnson has seen revenue growth, increasing from $78.7B in FY2021 to $94.2B in FY2025, driven by its Innovative Medicine's oncology franchise.

The valuation debate is ongoing, with InvestingPro's Fair Value model assigning a price of $249.03, indicating a potential 9.7% downside from current levels.